1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Andrew Rezvani: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Ibrutinib, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Andrew Rezvani | 8 | 2017-09-12 | 2023-08-01 |
Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
ibrutinib (1)
United States (1)